BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 951 filers reported holding BAXTER INTL INC in Q2 2014. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2014 | $34,000 | +41.7% | 469 | +37.9% | 0.01% | +25.0% |
Q3 2014 | $24,000 | -22.6% | 340 | -20.0% | 0.00% | -20.0% |
Q2 2014 | $31,000 | -77.5% | 425 | -77.4% | 0.01% | -76.2% |
Q1 2014 | $138,000 | -97.0% | 1,878 | -97.1% | 0.02% | -97.1% |
Q4 2013 | $4,581,000 | -1.5% | 65,860 | -7.0% | 0.72% | -7.1% |
Q3 2013 | $4,652,000 | -6.0% | 70,819 | -0.9% | 0.77% | -11.4% |
Q2 2013 | $4,949,000 | – | 71,450 | – | 0.87% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |